Nephrogenic systemic fibrosis
Nephrogenic systemic fibrosis (NSF), also known as nephrogenic fibrosing dermopathy, is a complication of gadolinium-based contrast agents used in MRI.
It is characterized by "firm, erythematous, and indurated plaques of the skin associated with subcutaneous edema" 1. Eventually, flexure contractures develop, with restriction to movement, pain and pruritus. Although the skin is primarily involved, many other organs (e.g. lungs, heart, diaphragm, liver, kidneys, esophagus, and skeletal muscles) can also be involved, eventually leading to death 7.
Application of preventive guidelines on usage of gadolinium based contrast agents in patients with reduced renal function has been shown to be extremely effective in protection of patient from NSF 5.
Screening
Patients should be screened for the possible risk of developing NSF by using institutional screening questionnaires and calculating the eGFR 2,7:
- history of renal disease: renal transplant (20% develop NSF), dialysis, single kidney, renal malignancy, renal surgery; should have eGFR checked
- liver failure patients: should have eGFR checked
- hypertension requiring medication
- diabetes mellitus
- outpatient screening (not on dialysis): eGFR use is controversial as they rarely develop NSF
Recommendations
Avoid gadolinium-containing contrast agents in patients whose:
- eGFR is <30 mL/min/1.73 m2
Cautionary use of gadolinium-containing contrast agents in patients whose 1,3:
- eGFR is <60 mL/min/1.73 m2
"When contrast-enhanced MR imaging is requested for a patient with renal insufficiency who is hospitalized due to major surgery, major infection, or a thrombotic vascular event, alternative imaging is indicated to avoid the use of gadolinium-based contrast agents; this decision should be made after consultation with the referring service and the patient" 1.
In cases where contrast still needs to be given 2:
- if eGFR <30 mL/min
- take informed consent (risk of NSF <1/10,000 patients with eGFR <30 mL/min)
- the maximum dose of 0.1 mmol/kg
- adequate hydration must be provided
- if the patient is on dialysis: (inpatient)
- MRI should be done just before dialysis as the contrast can be removed by subsequent dialysis
- some centers consider dialysis a strict contraindication
On this page:
Clinical presentation
- typically presents weeks to months after the administration of Gd
- typically involves the dermis in the extremities symmetrically, less commonly the trunk with the face spared, typically sparing the antecubital and popliteal fossae
- presentation resembles scleromyxedema or eosinophilic fasciitis
- skin lesions: hyperpigmented, thickened brawny induration
- joint contractures
- pain, pruritus, skin tightness or burning sensation
Pathology
The development of NSF with exposure to gadolinium-containing MRI contrast agents has been strongly reported in patients with moderate to end-stage renal impairment. This could be due to transmetallation, which is the replacement of the gadolinium from the chelate and forming a free gadolinium ion, free gadolinium ions may then deposit in different tissues and result in inflammation and fibrosis. Prolonged clearance times of gadolinium-based contrast agents in significant renal insufficiency contributes to this transmetallation process 7. Low stability gadolinium contrast media show the strongest association with NSF 3.
Additional positive risk factors include:
- concurrent infectious/inflammatory condition
- concurrent infarcted/ischemic tissue (e.g. peripheral arterial thromboembolism)
- recent surgery/trauma
Histology
- deep dermal biopsy required
- however findings are non-specific: thickened collagen bundle, mucin deposition, spindle cell proliferation, CD3 + fibroblasts
Contrast agents
The medical literature review has shown that ~78% of all unconfounded, single-agent cases of NSF have been associated with Omniscan® (gadodiamide), while ~20% have been associated with Magnevist® (gadopentetate dimeglumine), and less than 2%, with OptiMARK® (gadoversetamide) 4.
Radiographic features
- diffuse soft tissue tracer uptake on bone scans
- skin thickening and subcutaneous stranding on multiple modalities
- skin and muscle activity on PET
Treatment and prognosis
- no consistently effective therapy
- improved renal function: renal transplant, recovery from acute renal failure (ARF)
- physical therapy
- extracorporeal photopheresis, plasmapheresis, immunoglobulin therapy, steroids and other immunosuppressive agents
Related Radiopaedia articles
Imaging technology
- imaging technology
- imaging physics
- imaging in practice
-
x-ray
- x-ray physics
- x-ray in practice
- x-ray production
- x-ray tubes
- tube rating
- filters
- automatic exposure control (AEC)
- beam collimators
- grids
- air gap technique
- cassette
- intensifying screen
- x-ray film
- image intensifier
- digital radiography
- digital image
- mammography
- x-ray artifacts
- radiation units
- radiation safety
- radiation detectors
- fluoroscopy
-
computed tomography (CT)
- CT physics
- CT in practice
- CT technology
- CT image reconstruction
- CT image quality
- CT dose
- CT contrast media
-
CT artifacts
- patient-based artifacts
- physics-based artifacts
- hardware-based artifacts
- ring artifact
- tube arcing
- out of field artifact
- air bubble artifact
- helical and multichannel artifacts
- CT safety
- history of CT
-
MRI
- MRI physics
- MRI in practice
- MRI hardware
- signal processing
-
MRI pulse sequences (basics | abbreviations | parameters)
- T1 weighted image
- T2 weighted image
- proton density weighted image
- chemical exchange saturation transfer
- CSF flow studies
- diffusion weighted imaging (DWI)
- echo-planar pulse sequences
- fat-suppressed imaging sequences
- gradient echo sequences
- inversion recovery sequences
- metal artifact reduction sequence (MARS)
-
perfusion-weighted imaging
- techniques
- derived values
- saturation recovery sequences
- spin echo sequences
- spiral pulse sequences
- susceptibility-weighted imaging (SWI)
- T1 rho
- MR angiography (and venography)
-
MR spectroscopy (MRS)
- 2-hydroxyglutarate peak: resonates at 2.25 ppm
- alanine peak: resonates at 1.48 ppm
- choline peak: resonates at 3.2 ppm
- citrate peak: resonates at 2.6 ppm
- creatine peak: resonates at 3.0 ppm
- functional MRI (fMRI)
- gamma-aminobutyric acid (GABA) peak: resonates at 2.2-2.4 ppm
- glutamine-glutamate peak: resonates at 2.2-2.4 ppm
- Hunter's angle
- lactate peak: resonates at 1.3 ppm
- lipids peak: resonates at 1.3 ppm
- myoinositol peak: resonates at 3.5 ppm
- MR fingerprinting
- N-acetylaspartate (NAA) peak: resonates at 2.0 ppm
- propylene glycol peak: resonates at 1.13 ppm
-
MRI artifacts
- MRI hardware and room shielding
- MRI software
- patient and physiologic motion
- tissue heterogeneity and foreign bodies
- Fourier transform and Nyquist sampling theorem
- MRI contrast agents
- MRI safety
-
ultrasound
- ultrasound physics
-
transducers
- linear array
- convex array
- phased array
- frame averaging (frame persistence)
- ultrasound image resolution
- imaging modes and display
- pulse-echo imaging
- real-time imaging
-
Doppler imaging
- Doppler effect
- color Doppler
- power Doppler
- B flow
- color box
- Doppler angle
- pulse repetition frequency and scale
- wall filter
- color write priority
- packet size (dwell time)
- peak systolic velocity
- end-diastolic velocity
- resistive index
- pulsatility index
- Reynolds number
- panoramic imaging
- compound imaging
- harmonic imaging
- elastography
- scanning modes
- 2D ultrasound
- 3D ultrasound
- 4D ultrasound
- M-mode
-
ultrasound artifacts
- acoustic shadowing
- acoustic enhancement
- beam width artifact
- reverberation artifact
- ring down artifact
- mirror image artifact
- side lobe artifact
- speckle artifact
- speed displacement artifact
- refraction artifact
- multipath artifact
- anisotropy
- electrical interference artifact
- hardware-related artifacts
- Doppler artifacts
- aliasing
- tissue vibration
- spectral broadening
- blooming
- motion (flash) artifact
- twinkling artifact
- acoustic streaming
- biological effects of ultrasound
- history of ultrasound
-
nuclear medicine
- nuclear medicine physics
- detectors
- tissue to background ratio
-
radiopharmaceuticals
- fundamentals of radiopharmaceuticals
- radiopharmaceutical labeling
- radiopharmaceutical production
- nuclear reactor produced radionuclides
- cyclotron produced radionuclides
- radiation detection
- dosimetry
- specific agents
- carbon-11
- chromium-51
- fluorine agents
- gallium agents
- Ga-67 citrate
- Ga-68
- iodine agents
-
I-123
- I-123 iodide
- I-123 ioflupane (DaTSCAN)
- I-123 ortho-iodohippurate
- I-131
-
MIBG scans
- I-123 MIBG
- I-131 MIBG
-
I-123
- indium agents
- In-111 Octreoscan
- In-111 OncoScint
- In-111 Prostascint
- In-111 oxine labeled WBC
- krypton-81m
- nitrogen-13
- oxygen-15
- phosphorus-32
- selenium-75
-
technetium agents
- Tc-99m DMSA
- Tc-99m DTPA
- Tc-99m DTPA aerosol
- Tc-99m HMPAO
- Tc-99m HMPAO labeled WBC
- Tc-99m MAA
- Tc-99m MAG3
- Tc-99m MDP
- Tc-99m mercaptoacetyltriglycine
- Tc-99m pertechnetate
- Tc-99m labeled RBC
- Tc-99m sestamibi
- Tc-99m sulfur colloid
- Tc-99m sulfur colloid (oral)
- thallium-201 chloride
- xenon agents
- in vivo therapeutic agents
- pharmaceuticals used in nuclear medicine